Taro Fluocinonide Gel 0.05% Recall: Cross Contamination Risk
Taro Pharmaceuticals recalls 0.05% Fluocinonide Gel 15g tubes due to traces of Dapsone found in finished product. Rx-only medication may pose cross-contamination risk.
Lower-risk recall
Cross contamination with other products: traces of Dapsone were found in the finished product.
Contact the company
What happened, in plain English
Taro Pharmaceuticals is recalling 0.05% Fluoc: 15g tubes because traces of Dapsone were found in the product. This cross-contamination could affect medication safety for people using prescription topical steroids. Read more at govinfonow.com/recall/41244-taro-fluocinonide-gel-0-05-recall-cross-contamination-risk.
Source Summary by GovInfoNow · govinfonow.com/recall/41244-taro-fluocinonide-gel-0-05-recall-cross-contamination-risk · Updated October 7, 2026 · FDA enforcement record: FDA #D-0146-2018
Cite this page
“Taro Fluocinonide Gel 0.05% Recall: Cross Contamination Risk.” GovInfoNow, updated October 7, 2026. https://govinfonow.com/recall/41244-taro-fluocinonide-gel-0-05-recall-cross-contamination-risk. Based on FDA recall #D-0146-2018 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0146-2018%22&limit=1).
Why it’s dangerous
Traces of Dapsone, an antibiotic, were found in the finished gel product. This cross-contamination could lead to unintended medication interactions or allergic reactions in some users, though the risk is considered low.
Who’s affected
Prescription users of Fluocinonide Gel 0.05% 15g tubes. People with sensitive skin or those using the product for extended periods may be at slightly higher risk due to potential cross-contamination.
How to tell if you have this one
Check for 0.05% Fluocinonide Gel USP 15g tubes with NDC 51672-1279-1, manufactured by Taro Pharmaceuticals Inc. in Brampton, Ontario, Canada. The lot number A771026850 was produced until June 2018.
- Brand
Taro Pharmaceuticals- Category
Drug
What to do — step by step
Check Product Details
Verify the product's NDC number (51672-1279-1) and lot number (A771026850) to confirm if it's affected.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 3 years after the firm started it.
- Firm started the recall
- Published in FDA’s Enforcement Report
- FDA classified it Class III
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0146-2018 (September 20, 2017) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0146-2018 to see it in context.
- Plain-language summary written by qwen3:4b on October 7, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.